Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Dyne Therapeutics Inc’s stock clocked out at $24.87, up 4.23% from its previous closing price of $23.86. In other words, the price has increased by $4.23 from its previous closing price. On the day, 0.71 million shares were traded. DYN stock price reached its highest trading level at $25.185 during the session, while it also had its lowest trading level at $23.59.
Ratios:
To gain a deeper understanding of DYN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.53 and its Current Ratio is at 2.53. In the meantime, Its Debt-to-Equity ratio is 0.30 whereas as Long-Term Debt/Eq ratio is at 0.25.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on February 20, 2024, initiated with a Buy rating and assigned the stock a target price of $36.
On February 27, 2023, Raymond James Upgraded its rating to Strong Buy which previously was Outperform and also upped its target price recommendation from $16 to $27.
On February 15, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $34.Oppenheimer initiated its Outperform rating on February 15, 2023, with a $34 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 12 ’24 when Farwell Wildon sold 1,030 shares for $25.58 per share. The transaction valued at 26,347 led to the insider holds 150,560 shares of the business.
Brumm Joshua T sold 66,387 shares of DYN for $1,704,142 on Mar 11 ’24. The CEO & President now owns 537,998 shares after completing the transaction at $25.67 per share. On Mar 11 ’24, another insider, McNeill Jonathan, who serves as the Chief Business Officer of the company, sold 19,601 shares for $25.50 each. As a result, the insider received 499,842 and left with 139,408 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DYN now has a Market Capitalization of 2143239424 and an Enterprise Value of 1859775744.
Stock Price History:
Over the past 52 weeks, DYN has reached a high of $30.27, while it has fallen to a 52-week low of $6.40. The 50-Day Moving Average of the stock is -3.98%, while the 200-Day Moving Average is calculated to be 63.33%.
Shares Statistics:
It appears that DYN traded 1.41M shares on average per day over the past three months and 810470 shares per day over the past ten days. A total of 61.47M shares are outstanding, with a floating share count of 51.59M. Insiders hold about 36.39% of the company’s shares, while institutions hold 57.66% stake in the company. Shares short for DYN as of 1711584000 were 8077008 with a Short Ratio of 5.71, compared to 1709164800 on 6609667. Therefore, it implies a Short% of Shares Outstanding of 8077008 and a Short% of Float of 11.55.
Earnings Estimates
The dynamic stock of Dyne Therapeutics Inc (DYN) is currently attracting attention from Devon Energy Corporation analysts actively involved in rating its market status.The consensus estimate for the next quarter is $291.31, with high estimates of $2.00 and low estimates of $11.84.
